血友病A・血友病Bの組換え因子補充療法:世界の薬剤市場予測・分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 24
2.3 Upcoming Related Reports 24
3 Disease Overview 25
3.1 Etiology and Pathophysiology 25
3.1.1 Etiology 25
3.1.2 Pathophysiology 26
3.1.3 Prognosis and Quality of Life 28
3.2 Symptoms 29
3.2.1 Hemophilia A and B 29
3.2.2 Inhibitors 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 32
4.3 Global Trends 33
4.4 Forecast Methodology 35
4.4.1 Sources Used 35
4.4.2 Sources Not Used 36
4.4.3 Forecast Assumptions and Methods 37
4.5 Epidemiological Forecast for Hemophilia A (2014-2024) 41
4.5.1 Diagnosed Prevalent Cases of Hemophilia A 41
4.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age 42
4.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex 44
4.5.4 Age-Standardized Diagnosed Prevalence of Hemophilia A 46
4.6 Epidemiological Forecast for Hemophilia B (2014-2024) 47
4.6.1 Diagnosed Prevalent Cases of Hemophilia B 47
4.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age 49
4.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex 51
4.6.4 Age-Standardized Diagnosed Prevalence of Hemophilia B 53
4.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2014-2024) 54
4.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 54
4.7.2 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex 56
4.8 Discussion 58
4.8.1 Conclusions on Epidemiological Trends 58
4.8.2 Limitations of the Analysis 59
4.8.3 Strengths of the Analysis 60
5 Disease Management 61
5.1 Treatment Overview 61
5.1.1 Hemophilia A and B Diagnosis 61
5.1.2 Hemophilia A and B Treatment 62
5.1.3 Diagnosis of Inhibitors 64
5.1.4 Treatment of Inhibitors 65
5.2 US 67
5.2.1 Clinical Practice 67
5.3 France 69
5.3.1 Clinical Practice 69
5.4 Germany 71
5.4.1 Clinical Practice 71
5.5 Italy 73
5.5.1 Clinical Practice 73
5.6 Spain 75
5.6.1 Clinical Practice 75
5.7 UK 77
5.7.1 Clinical Practice 77
5.8 Japan 79
5.8.1 Clinical Practice 79
5.9 Argentina 81
5.9.1 Clinical Practice 81
6 Competitive Assessment 83
6.1 Overview 83
6.2 Strategic Competitive Assessment 83
6.3 Product Profiles – Hemophilia A 86
6.3.1 Advate (Octocog Alfa) 86
6.3.2 Kogenate FS/Helixate FS (Octocog Alfa) 92
6.3.3 Xyntha/ReFacto AF (Moroctocog Alfa) 99
6.3.4 Recombinate (Octocog Alfa) 103
6.3.5 Eloctate (Efmoroctocog Alfa) 107
6.3.6 NovoEight (Turoctocog Alfa) 113
6.3.7 Nuwiq (Simoctocog Alfa) 118
6.4 Product Profiles – Hemophilia B 123
6.4.1 BeneFIX (Nonacog Alfa) 123
6.4.2 Alprolix (Eftrenonacog Alfa) 128
6.4.3 Rixubis (Nonacog Gamma) 134
6.4.4 IXinity (Trenonacog Alfa) 138
6.5 Product Profiles – Hemophilia A and B with Inhibitors 143
6.5.1 NovoSeven RT (Eptacog Alfa) 143
7 Opportunity and Unmet Need 149
7.1 Overview 149
7.2 Opportunity Analysis 150
7.2.1 Longer-Lasting Recombinant Factors 150
7.2.2 Lower-Cost Recombinant Replacement Therapies 151
7.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 153
7.2.4 More Convenient Drug Administration 154
7.3 Unmet Needs Gap Analysis 154
7.3.1 Long-Acting FVIII Replacement Therapies 154
7.3.2 Gene Therapy Treatments for Hemophilia A and B 155
8 Pipeline Assessment 157
8.1 Overview 157
8.2 Late-Stage Development Candidates – Hemophilia A 158
8.2.1 Kovaltry (Octocog Alfa; BAY 81-8973) 159
8.2.2 Adynovate (BAX-855) 164
8.2.3 BAY 94-9027 (Damoctocog Alfa Pegol) 169
8.2.4 N8-GP (Turoctocog Alfa Pegol) 175
8.2.5 CSL-627 (rFVIII-SC) 181
8.2.6 GreenGene F (Beroctocog Alfa; GC1101C) 186
8.3 Late-Stage Development Candidates – Hemophilia B 192
8.3.1 CSL-654 (rIX-FP; Albutrepenonacog Alfa) 193
8.3.2 N9-GP (NN-7999; Nonacog Beta Pegol) 197
8.4 Late-Stage Development Candidates – Hemophilia A and B Bypassing Agents (Patients with Inhibitors) 203
8.4.1 BAX-817 (rFVIIa BI) 204
8.4.2 LR-769 (rhFVIIa) 209
8.4.3 CSL-689 (rVIIa-FP) 215
8.5 Promising Drugs in Early-Stage Development 220
8.5.1 Alternative Coagulation Promoters 220
8.5.2 Gene Therapies 223
9 Current and Future Players 227
9.1 Overview 227
9.2 Trends in Corporate Strategy 229
9.3 Company Profiles 229
9.3.1 Baxalta 229
9.3.2 Bayer 233
9.3.3 Biogen 235
9.3.4 CSL Behring 237
9.3.5 Novo Nordisk 239
9.3.6 Pfizer 242
10 Market Outlook 244
10.1 Global Markets 244
10.1.1 Forecast 244
10.1.2 Drivers and Barriers – Global Market 247
10.2 US 250
10.2.1 Forecast 250
10.2.2 Key Events 254
10.2.3 Drivers and Barriers 254
10.3 5EU 255
10.3.1 Forecast 255
10.3.2 Key Events 259
10.3.3 Drivers and Barriers – France 260
10.3.4 Drivers and Barriers – Germany 262
10.3.5 Drivers and Barriers – Italy 263
10.3.6 Drivers and Barriers – Spain 264
10.3.7 Drivers and Barriers – UK 265
10.4 Japan 266
10.4.1 Forecast 266
10.4.2 Key Events 270
10.4.3 Drivers and Barriers 270
10.5 Argentina 272
10.5.1 Forecast 272
10.5.2 Key Events 277
10.5.3 Drivers and Barriers 277
11 Appendix 279
11.1 Bibliography 279
11.2 Abbreviations 306
11.3 Methodology 309
11.4 Forecasting Methodology 309
11.4.1 Diagnosed Hemophilia Patients 309
11.4.2 Percent Drug-Treated Patients 310
11.4.3 Drugs Included in Each Therapeutic Class 310
11.4.4 Launch Dates 311
11.4.5 General Pricing Assumptions 312
11.4.6 Individual Drug Assumptions 313
11.4.7 Pricing of Pipeline Agents 322
11.5 Primary Research – KOLs Interviewed for this Report 323
11.6 Primary Research – Prescriber Survey 327
11.7 Real-World Data 327
11.8 About the Authors 329
11.8.1 Analyst 329
11.8.2 Therapy Area Director 329
11.8.3 Epidemiologists 329
11.8.4 Global Head of Healthcare 331
11.9 About GlobalData 332
11.10 Disclaimer 332


【レポート販売概要】

■ タイトル:血友病A・血友病Bの組換え因子補充療法:世界の薬剤市場予測・分析
■ 英文:PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024
■ 発行日:2015年12月
■ 調査会社:GlobalData
■ 商品コード:GDHC116PIDR
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。